| 0.027 Data as of Jun 17 | -0.0039 / -12.62%Today’s Change | 0.02 Today|||52-Week Range 0.32 | -82.58% Year-to-Date |
| SECTOR Health Technology | INDUSTRY Biotechnology | MARKET CAP $5.3M |
Company Description
Senesco Technologies, Inc. is a development stage company which develops cancer therapeutics products. Its current focus is to utilize the patented and patent-pending technology related to certain genes, primarily eukaryotic translation initiation Factor 5A and deoxyhypusine synthase, and related technologies for human therapeutic applications to develop novel approaches to treat cancer and inflammatory diseases. The company has developed a therapeutic candidate, SNS01-T, for the potential treatment of multiple myeloma. Senesco Technologies was founded in 1999 and is headquartered in Bridgewater, NJ.
Employees

Shareholders
| Individual stakeholders | 15.62% |
| Mutual fund holders | -- |
| Other institutional | -- |
Top Executives
| Leslie J. Browne, PhD | President, Chief Executive Officer & Director |
| Jack van Hulst | Director |
| Joel P. Brooks | Chief Financial Officer, Secretary & Treasurer |
| Richard S. Dondero | Vice President-Research & Development |
| John E. Thompson, PhD | Director, CSO, Executive VP-Research & Development |